Polyethylene Glycol 3350 NF

Manufacturer
MARTIN EKWEALOR PHARMACEUTICALS, INC.
Effective date
2013-12-13
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:17:57

Label at a glance#

ProductPolyethylene Glycol 3350 NF PEGyLAX
Active ingredientPOLYETHYLENE GLYCOL 3350
Label structure16 sections

Indications and uses

For the treatment of occasional constipation. This product should be used for 2 weeks or less as directed by a physician.

Dosage and administration

1. Note: This product cap is for dosing. A capful contains about 17 grams of powder. 2. Daily dose is 17 grams per day or as directed by physician. 3. pour 17 grams (about 1 heaping tablespoon) of powder into a cup. 4. Stir the powder in 4 to 8 oz. of water, juice, soda, coffee or tea until completely dissolved. 5. Drink the solution. 6. Treatment for 2 to 4 days may required to produce a bowel movement. Keep this...

Storage and handling

Store at 20°-25°C (68°-77°F): excursions permitted to 15°-30°C (59°-86°F). (See USP Controlled Room Temperature)

Label contents#

Full prescribing information#

Directions

DOSAGE & ADMINISTRATION SECTION

1. Note: This product cap is for dosing. A capful contains about 17 grams of powder.

2. Daily dose is 17 grams per day or as directed by physician.

3. pour 17 grams (about 1 heaping tablespoon) of powder into a cup.

4. Stir the powder in 4 to 8 oz. of water, juice, soda, coffee or tea until completely dissolved.

5. Drink the solution.

6. Treatment for 2 to 4 days may required to produce a bowel movement.

Keep this and all medications out of the reach of children.

Store at 20° - 25° C (68° - 77° F); excursions permitted to 15° - 30°(59° - 86° F). (See USP Controlled Room Temperature)

Lot # and Exp. Date:

Open here for more product information

PATIENT INFORMATION

INFORMATION FOR PATIENTS SECTION

Polyethylene Glycol 3350 NF (Polyethylene Glycol 3350 Powder for Oral Solution) is a MEDICAL FOOD prescription only laxative which has been prescribed by your healthcare provider to manage constipation. This product should only be used by the person for whom it was prescribed.

How to take

The dose is 17 grams taken by mouth each day or as directed by your healthcare provider. Measure the dose using the product cap (or use one heaping tablespoon of powder), stir and dissolve in a glass (4 to 8 oz.) of water, juice, soda, coffee, or tea. Taking more than the prescribed dose may cause loss of fluid due to severe diarrhea.

How it will work

Polyethylene Glycol 3350 NF(PEG 3350)NF) softens the stool and increases the frequency of bowel movements by retaining water in the stool. Your first bowel movement will usually happen in two to four days, although results may vary for individual patients.

How long should it take

Polyethylene Glycol 3350 NF achieves the best results when used between one and two weeks. You may discontinue therapy after you have had several satisfactory bowel movements or diarrhea. Should unusual cramps, bloating, or diarrhea occur, consult your physician. Polyethylene Glycol 3350 NF is intended for up to a two week course of therapy. You should not use for a longer time unless directed by your physician.

Next Steps

After successfully completing Polyethylene Glycol 3350 NF therapy (usually between one and two weeks,) please discuss with your healthcare provider lifestyle changes which may produce more regular bowel habits such as adequate dietary and fluid intake, and regular exercise.

Who should not take Polyethylene Glycol 3350 NF

PEG 3350 NF should not be used by children and pregnant women unless prescribed by a physician.

Side Effects/Drug Reactions

Occasionally, Polyethylene Glycol 3350 NF may cause nausea, stomach fullness, cramping, diarrhea and /or gas. Do not take if you have symptoms such as nausea, vomiting, abdominal pain or distension, which may be due to bowel obstruction. On a rare occasions hives and skin rashes have been reported which are suggestive of an allergic reaction. If you get an allergic reaction reaction, you should stop using PEG 3350 NF, and call your physician. if you are allergic to polyethylene glycol, do not use this product.

Polyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution

DESCRIPTION SECTION

A white powder for reconstitution. Polyethylene Glycol 3350 (Polyethylene Glycol 3350 Powder For Oral Solution) is a synthetic polyglycol having an average molecular weight of 3350. The actual molecular weight is not less than 90.0 percent and not greater than 110.0 percent of the normal  value. The chemical formula is HO(C2H4O)nH in which n represents the average number of ethylene groups. Below 55°  it is a free flowing white powder freely soluble in water. Polyethylene Glycol 3350 NF is an osmotic agent for the treatment of constipation.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Pharmacology: Polyethylene Glycol 3350 NF is an osmotic agent which causes water to be retained with the stool. Essentially, complete recovery of Polyethylene Glycol 3350 NF was shown in normal subjects without constipation. Attempts at recovery of Polyethylene Glycol 3350 NF in constipated patients resulted in incomplete and highly variable recovery. In vitro study showed indirectly that Polyethylene Glycol 3350 NF was not fermented into hydrogen or methane by the colonic mircoflora in human feces. Polyethylene Glycol 3355 NF appears to have no effect on the active absorption or secretion of glucose or electrolytes. There is no evidence of tachyphylaxis.

CLINICAL TRIALS

CLINICAL STUDIES SECTION

In one study, patients with less than 3 bowel movements per week were randomized to Polyethylene Glycol 3350 NF, 17 grams or placebo for 14 days. An increase in bowel movement frequency was observed for both treatment groups during the first week of treatment. Polyethylene Glycol 3350 NF was statistically superior to placebo during the second week of treatment. In another study, patients with 3 bowel movements or less per week and/or less than 300 grams of stool per week were randomized to 2 dose levels of Polyethylene Glycol 3350 NF or placebo for 10 days each. Success was defined by an increase in both bowel movement frequency and daily stool weight. For both parameters, superiority of the 17 gram dose of Polyethylene Glycol 3350 NF over the placebo was demonstrated.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the treatment of occasional constipation. This product should be used for 2 weeks or less as directed by a physician.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Polyethylene Glycol 3350 NF is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.

WARNINGS

WARNINGS SECTION

Patients with symptoms suggestive of bowel obstruction (nausea, vomiting, abdominal pain or distention) should be evaluated to rule out this condition before initiating Polyethylene Glycol 3350 NF therapy.

PRECAUTIONS

PRECAUTIONS SECTION

General: Patients presenting with complaints of constipation should have a thorough medical history and physical examination to detect associated metabolic endocrine and neurogenic conditions and medications. A diagnostic evaluation should include a structural examination of the colon. Patients should be educated about a good defecatory and eating habits (such as high fiber diets) and lifestyle changes (adequate dietary fiber and fluid intake, regular exercise) which may produce regular bowel habits.

Polyethylene Glycol 3350 NF should be administered after being dissolved in approximately 4 to 8 ounces of water, juice, soda, coffee,or tea.

Information for Patients:
Polyethylene Glycol 3350 NF softens stool and increases the frequency of bowel movement by retaining water in the stool. It should always be taken by mouth after being dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea. Should unusual cramps, bloating or diarrhea occur, consult your physician.

Two to four days may be required to produce a bowel movement. This product should be used for 2 weeks or less or as directed  by your physician. prolonged, frequent or excessive use of Polyethylene Glyycol 3350 NF may result in electrolyte imbalance and dependency on laxatives.

Laboratory Tests: No clinically significant effects on laboratory tests have been demonstrated.

Drug Interaction: No specific drug interactions have been demonstrated.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long term  carcinogenicity studies, genetic toxicity studies or reproductive toxicity studies in animals have not been performed with  Polyethylene Glycol 3350 NF.

Pregnancy: Category C. Animal reproductive studies have not been performed with Polyethylene Glycol 3350 NF. It is not known wheter Polyethylene Glycol 3350 NF can cause fetal harm when administered in a pregnant woman, or can affect reproductive capacity. Polyethylene Glycol 3350 NF should only be administered to a pregnant woman if clearly needed.

Pediatric Use: Safety and effectiveness in pediatric patients has not been established.

Geriatric Use: There is no evidence for special consideration when Polyethylene Glycol 3350 NF is administered to elderly patients. In geriatric nursing home patients a higher incidence of diarrhea occurred at the recommended 17 g dose. If diarrhea occurs Polyethylene Glycol 3350 NF should be discontinued..

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Nausea, abdominal bloating, cramping and flatulence may occur. High doses may produce diarrhea and excessive stool frequency, particularly in elderly nursing home patients. Patients taking other medications containing polyethylene glycol occasionally developed hives suggestive of an allergic reaction.

OVERDOSE

OVERDOSAGE SECTION

There have been no reports of accidental overdose. In the event of overdose, diarrhea would be the expected major event. If an overdose occurred without conomitant ingestion of fluids, dehydration due to diarrhea may result. Treatment should be terminated and free water administered. The oral LD50 is >50g/kg in mice, rats and rabbits.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The usual dose is 17 grams (about 1 heaping tablespoon) of powder in 4 to 8 ounces of water, juice, soda, coffee or tea daily or as directed by physician. Each bottle of Polyethylene Glycol 3350 NF has a cap that holds 17 grams of laxative powder when filled to the top.Two to four days (48 to 96 hours0 may be required to produce a bowel movement.

HOW SUPPLIED

HOW SUPPLIED SECTION

PEG 3350 NF is supplied in powder form for oral administration after dissolution in water, juice, soda, coffee, or tea.

Rx only.

Keep this and all medication out of the reach of children.

GENERAL PRECAUTIONS SECTION

Keep this and all medication out of the reach of children.

STORAGE

STORAGE AND HANDLING SECTION

Store at 20°-25°C (68°-77°F): excursions permitted to 15°-30°C (59°-86°F).

(See USP Controlled Room Temperature)

Product Label Product Insert

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

M.E. Pharmaceuticals, Inc.

58607-700-57

Prescription Powder for Oral Solution


Polyethylene

Gylcol 3350 NF

PEGyLAX

Rx Only

527 Grams

MADE WITH PRIDE IN THE U.S.A.

M.E. Pharmaceuticals, Inc.

Richmond, IN 47374


ME PolyGlycol LabelME PolyGlycol Label


ME PolyGlycol1 LabelME PolyGlycol1 Label


ME PolyGlycol2 LabelME PolyGlycol2 Label


ME PolyGlycol3 LabelME PolyGlycol3 Label

ME PolyGlycol4 LabelME PolyGlycol4 Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1488067PEGyLAX 17 GM Powder for Oral SolutionPSN1
876193polyethylene glycol 3350 17 GM Powder for Oral SolutionPSN1
1488067polyethylene glycol 3350 17000 MG Powder for Oral Solution [Pegylax]SBD1
876193polyethylene glycol 3350 17000 MG Powder for Oral SolutionSCD1
1488067Pegylax 17 GM Powder for Oral SolutionSY1
876193polyethylene glycol 3350 17 GM Powder for Oral SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
POLYETHYLENE GLYCOL 3350 Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
d723478e-ad4a-ec23-6bd7-cfe33e1e3840Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
58607-700-572019-11-27C16284748780-19855e2a2-352b-60a7-e053-dbdaa90a05bdbcd57d3c-e1c4-474f-a757-ca89b020278b

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
58607-700-57Polyethylene Glycol 3350 NFPEGyLAX527 g in 1 BOTTLEPOWDER, FOR SOLUTION5271

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
58607-700POLYETHYLENE GLYCOL 3350 NF PEGYLAX (POLYETHYLENE GLYCOL 3350) POWDER, FOR SOLUTION [MARTIN EKWEALOR PHARMACEUTICALS, INC.]1Legacy NDC, 1 package rows20140204_bcd57d3c-e1c4-474f-a757-ca89b020278b.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
POLYETHYLENE GLYCOL 3350ACTIVE INGREDIENTG2M7P15E5P1
POLYETHYLENE GLYCOL 3350ACTIVE MOIETYG2M7P15E5P1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
58607-70058607-700-57

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
POLYETHYLENE GLYCOL 3350G2M7P15E5PACTIB

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
7622102b-138b-4991-91dd-72eeeb58f2b8bcd57d3c-e1c4-474f-a757-ca89b020278b2013-12-13Warnings, Adverse reactionsExact identifier
spl id: 7622102b-138b-4991-91dd-72eeeb58f2b8
spl set id: bcd57d3c-e1c4-474f-a757-ca89b020278b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.